drugset / Trial / NCT05528887
Study of CAR-T Cell Therapy in the Treatment of Relapsed/Refractory Hematological Malignancies
Phase 1
Unknown
10 enrolled
The Affiliated People's Hospital of Ningbo University
UTC Therapeutics Inc. · collab
NaSingle-groupOpen-labelTreatment
Summary
The primary purpose of this study is to determine the safety and efficacy of novel autologous CAR-T cells in patients with relapsed/refractory hematological malignancies.
Timeline
- Start
- 2021-09-16
- Primary completion
- 2024-06
- Completion
- 2026-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Autologous CAR-T cells | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | 500 mg/m2 | Intravenous |
| Background | Fludarabine | Small molecule | 30 mg/m2 | Intravenous |